CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today at a presentation in New York City will discuss pipeline progress across its three strategic therapeutic areas (STArs) including: Genetic Medicines, Cardio-Metabolic Disease, and Hepatic Infectious Disease. The Company’s management will profile their mid-to-late stage RNAi therapeutic programs, specifically discussing the unmet medical need, clinical development plans and market potential for several innovative investigational medicines. In January 2016, the Company expects to provide additional specific 2016 guidance on pipeline programs in its three STArs.
